Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced death risk by 67%.
New findings suggest active surveillance should be performed in this population and should not preclude transplant eligibility, according to investigators.
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Study revealed an objective response rate consistent with that observed in the CheckMate 214 clinical trial and a low rate of treatment-related adverse events.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma compared with a matched control group of patients without cancer, a study found.
Investigators report a cumulative 10-year incidence of end-stage kidney disease of 2.5% among patients who undergo surgery for renal cell carcinoma (RCC), which is 10 times higher than in patients without RCC.
Intraoperative pathologic assessment of tissue adjacent to the neurovascular bundles after removal of the prostate increases the likelihood of nerve-sparing surgery.
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
